Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Sultan Qaboos University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07342764CT.gov Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial | — | Not Yet Recruiting | — | — | — |
NCT07120828CT.gov The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity | — | Completed | — | — | — |
NCT06000462CT.gov The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes | — | Active Not Recruiting | — | — | — |
NCT06383832CT.gov Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet. | — | Completed | — | — | — |
NCT03710460CT.gov Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity | — | Unknown | — | — | — |
NCT03961659CT.gov Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy. | — | Unknown | — | — | — |
NCT03419624CT.gov The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients | — | Terminated | — | — | — |
NCT03361098CT.gov DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 | — | Completed | — | — | — |
NCT03089333CT.gov Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects | — | Completed | — | — | — |
NCT02635386CT.gov EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT02695810CT.gov The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes | — | Completed | — | — | — |
NCT02313220CT.gov Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dapagliflozin (this asset) | Sultan Qaboos University | Approved | BB · 67 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Dapagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 77 |
| Arteriosclerosis Disorder | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dapagliflozin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dapagliflozin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →